T HE most effective therapy currently available for patients with anaplastic gliomas is radiotherapy to the head accompanied by chemotherapy with 1,3-bis(2-chloroethyl)-l-nitrosourea (BCNU). These adjunctive therapies following surgery have more than doubled the anticipated survival time (approximately a year) following surgery compared to the period of survival expected with surgery alone. 26 At this time, no more effective regimens have come to the forefront, despite ongoing investigations of the use of radiosensitizers, interstitial radiation, hyperthermia, and other chemotherapeutic agents. 3'7'~2'25 Immunotherapy as a treatment modality has obvious fascination and scientific appeal. Four forms of immunotherapy might be considered: immune adjuvants, serotherapy, adoptive immunotherapy, and active immunotherapy. Although the literature contains reports of all four forms of immunotherapy being applied to patients with anaplastic gliomas, 9' ~-~ 3,17-19,23,24,28 none of these earlier studies has reported specific immune reactions by patients undergoing immunotherapy, and only one report has made an unequivocal attempt to determine efficacy of therapy: the prospective active immunotherapy, without adjuvant, reported by Bloom, et al. s We report here the clinical aspects of a study of selected nonrandomized patients actively immunized with a glioma preparation plus adjuvant, for evaluation of relative safety and assessment of serial general immune responses. More specific immune reactions of these patients are reported in Part 8) 6 -54MG cell group  1  AI, A24,  2  1155  55  100  B7, B8  2  AI, A24,  3  2717  78  90  BS, BI8  3  A2, B40  2  1599  86  100  4  AI, A25,  1  1995  88  90  B8, BI8  5  A2, A28,  4  1850  78  100  B7, B44  6  A24, A26,  2  3022  76  100  B8, B44  7  A3, B15,  3  2627  84  100  B50  8  A26, A32,  2  1508  73  80  B51  9  A29, A32,  l  1772  81  100  BS, B44  10  A330 A34,  3  1610  66  100  B49  11  not tested  1  1222  66  100  U-251MG cell group  12  A3, AI 1,  2  2132  76  100  BI7, B22  13  A2, A31,  1  2352  72  100  B7, B18  14  A2, A3,  2  2002  62  100  B35, BI7  15  A24, A29,  1  1335  75  100  B45, B51  16  A2, A3,  1  1592  86  70  BI5, B44  17  A1, AI 1,  2  1790  77  90  BI7  18  A24, A25,  2  1130  76  90  B52  19  A2, A31,  1  2275  88  90  B7, BI8  20  A3, A24,  1  1260  74  90  B7, B40 * HLA = human lymphocyte antigen; DHR = delayed hypersensitivity reactions.
t Mean T-cell values for controls: 76% + 9%.
Clinical Material and Methods

Patient Selection
Twenty patients were selected who had undergone subtotal resections of supratentorial anaplastic gliomas within 3 weeks of entry into the study. All patients were adults (above the age of 18 years) and met all the following clinical criteria in order to be candidates for inclusion in this study: 1) positive delayed hypersensitivity reactions (DHR's) at 48 hours to at least one of four recall antigens (streptokinase-streptodornase (SK-SD), purified protein derivative (PPD), mumps, or Trichophyton); 2) a Karnofsky Functional Rating ~4 equal to or greater than 70; 3) a peripheral blood lymphocyte M. S. Mahaley, Jr., et al. count equal to or greater than 1000 cells/cu mm; 4) Tcells in the peripheral blood equal in quantity to at least one-half that of control patients without tumor; and 5) not receiving steroid therapy (Table 1) . Histocompatibility antigen (HLA) typing was carried out using lymphocytes from each patient, employing 120 reagent antisera.
Active Immunization
Following the signing of informed consent, each patient underwent baseline neurological examination and computerized tomography (CT) brain scanning. A 1-ml saline suspension of 108 tissue-cultured glioma cells (lethally irradiated with 20,000 rads from a cobalt source) was divided equally and inoculated into four subcutaneous sites (each deltoid and anterior thigh area). The first 11 patients received the D -5 4 M G glioma cell line, and the next nine patients received the U-251MG cell line. Each of these cell lines has been established for a number of years and has been characterized by several biological criteria. 5 Neither o f these two cell lines, when inoculated along with Freund's complete adjuvant into n o n h u m a n primates, caused allergic encephalomyelitis, although both cell lines evoked a glioma-specific antibody response. 6 The first inoculum only for each patient was mixed with an equal volume of saline containing 500 ug bacillus Calmette-Gurrin cell wall (BCG-CW) adjuvant. .4 In addition, each patient received levamisole immunostimulation (2.5 mg/kg) orally three times weekly, every other week for a maximum of 18 months. Subcutaneous inoculation of 10 s cultured glioma cells (without adjuvant) was repeated monthly for a maximum of 18 months. Each of the two glioma lines used in this study is maintained in a tissue culture using Richter's zincoption modification 2' of Dulbecco's minimum essential medium (ZO-MEM), supplemented to 20% with endotoxin-free fetal bovine serum (FBS), and has been consistently free of Mycoplasma contamination.
Other Therapy and Follow-up Tests
One month after the first immunization, each patient also began conventional therapy which consisted of cobalt radiotherapy to the whole head (6000 rads over 6 weeks) and BCNU chemotherapy (80 mg/sq m intravenously per day for 3 days, every 2 months; bimonthly dosages were reduced 25% based upon hematological cytopenia criteria). For those patients who reached a cumulative dose of BCNU of 1400 mg/sq m, chemotherapy with BCNU was discontinued because of the risk of pulmonary interstitial fibrosis, and each such patient was begun on chemotherapy with procarbazine, 150 mg/sq m orally/day for 28 days every 8 weeks.
* The BCG-CW was supplied by the late Dr. Herbert Rapp, National Cancer Institute, Bethesda, Maryland.
The following general immunological assays, performed prior to beginning active immunization, were carried out bimonthly for a maximum of 18 months: skin testing with the four recall antigens, peripheral blood lymphocyte count, peripheral blood T-cell quantitation, and serum immunoglobulin (Ig) levels. Each patient was also evaluated bimonthly by neurological examination, Karnofsky Function Rating, and CT brain scanning. Relapse was defined as neurological deterioration associated with CT findings suggesting tumor growth. Survival times to relapse and to death were noted. When postmortem material was available, careful neuropathological examination of the central and peripheral nervous system was performed.
Results
Of the 20 patients entered into this study, 11 were inoculated with the D-54MG cell line and nine with the U-251MG cell lines. Although none of these patients was receiving steroid therapy at the time of entry into the study, one patient (Case 11) had to be placed on a course of steroids within 6 weeks because of neurological deterioration while receiving radiotherapy, and six were given steroids at the time of their relapse, usually many months after completion of radiotherapy. Local skin reactions beyond 48 hours occurred only at the initial inoculation sites where tumor cells were accompanied by the BCG-CW adjuvant (Fig. 1) . The degree of local reaction 30 days after each monthly immunization is shown in patients showed no local reactions; four of these six received the U-251MG cell line. Four (20%) of the 20 patients developed 3+ responses locally with spontaneous drainage and ulceration of the skin; these patients each received D-54MG inoculations. All reactions eventually healed without permanent sequelae.
Side effects associated with the administration of levamisole were anorexia and epigastric discomfort (five patients), fever (two patients), and rash (one patient). These side effects necessitated discontinuation of this drug in eight (40%) of 20 patients between 1 and 7 months after beginning therapy. Each patient completed the full course of radiotherapy prescribed. Five (25%) of the 20 patients developed arthritic-like joint pains from 2 to 5 months after initiation of therapy, and were treated with analgesics. Four (20%) of the 20 patients developed dementia from 5 to 10 months after beginning treatment. Differential diagnosis for this dementia included radionecrosis, tumor spread via the cerebrospinal fluid (CSF), or allergic response in the central nervous system. Therefore, CSF was examined by lumbar puncture in three of these four patients, for comparison with similar CSF from several patients in this study without dementia and from other control patients with similar therapy without glioma cell and (Table 3) . Each patient's age, pathological diagnosis, experience with chemotherapy, and period of survival are outlined in Table 4 . Ages ranged from 29 to 68 years (average 51 years), with the average age for patients inoculated with D-54MG being 50.6 years, and 51.4 years for those receiving U-251MG. Nine males and two females were inoculated with D-54MG, while five males and four females received U-251MG. The average cumulative amount of BCNU and number of chemotherapy treatment cycles administered to the 1 1 patients inoculated with D-54MG were 819 mg/sq m in five cycles, respectively, while the nine patients inoculated with U-251MG received an average of 1188 mg/sq m in eight cycles. Five (25%) of the 20 patients reached maximum tolerable total dose of BCNU and were switched to procarbazine. Using this approach to BCNU chemotherapy, 2 no patients developed symptoms of pulmonary interstitial fibrosis.
M. S. Mahaley, Jr., et al.
The results of serial general immunological screening studies (exclusive of serological immune data) are shown in Figs. 2 to 5 and do not differ significantly from those previously described in two separate studies prior to this investigation. ~5'18 The trend of gradual decline in DHR's, lymphocyte counts, T-cells, and serum IgM was unaltered by active immunization. In seven (35%) of 20 patients the PPD skin test which was initially negative became positive (perhaps related to revealed no evidence of an untoward reaction (such as allergic encephalomyelitis or allergic neuritis) to the immunotherapy.
Pathological changes in the skin and subcutis at the injection sites varied from no discernible lesion to mild chronic inflammation and scarring of the dermis and subcutis. A small collection of epithelioid macrophages was found in the dermis in one of the four injection sites in Case 7.
Discussion
Active immunotherapy with the protocol outlined in this report was well tolerated by 20 patients with anaplastic gliomas. In the three cases autopsied thus far, there was no neuropathological evidence of allergic encephalitis within the central or peripheral nervous systems. The several instances of clinical dementia were M. S. Mahaley, Jr., et al. similar to functional changes observed in other glioma patients treated with radiotherapy and chemotherapy alone. This syndrome was not associated with any elevation of BP content in the CSF. This phenomenon is thus far poorly understood, and studies are currently underway to evaluate this observation prospectively, to correlate any dementia observed with CT and other evidence of tumor recurrence, radiotherapy and chemotherapy data, and other individual patient characteristics.
Following immunization, only a few patients with negative PPD skin test reactions had positive findings, and then only for a brief period. Also, very few patients developed positive DHR's to an antigenic preparation of the immunizing cell line. The most prominent reactions at the site of initial immunization occurred in patients who received the D-54MG cell line. Other serological studies performed on these patients are included in a separate report. '6 In a study of this type, not controlled and not randomized, it is not possible to determine therapeutic efficacy. The four patients with anaplastic astrocytomas (not glioblastoma) are currently alive with no evidence of progression of disease at 675 to 1091 days (as of January 31, 1983) from the beginning of therapy. An intriguing finding referable to survival time was the relatively favorable response of the nine patients inoculated with the U-251MG cell line: seven (78%) of the nine were alive at 1 year, compared with four (40%) of the 10 patients who received D-54MG, and six (67%) of the nine U-251MG patients were alive at 1 89 years, compared with three (30%) of 10 who received D-54MG. This difference in survival between the U-251MG-and the D-54MG-inoculated patients does not appear to be due to any differences between the two groups as regards factors known to influence survival regardless of therapy: age, functional capacity, FtG. 6. Survival graphs comparing the patients treated in this study with U-251MG or D-54MG inoculations with those from a previous study treated only with radiotherapy, chemotherapy, and levamisole. TM histopathology grade, or CT brain scan characteristics (Table 5) at time of entry into the study. This finding is somewhat extraordinary and warrants further clinical and immunological evaluation.
